

Marion Delcroix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1626450/publications.pdf>

Version: 2024-02-01

183
papers

19,575
citations

31976

53
h-index

11308

136
g-index

185
all docs

185
docs citations

185
times ranked

11513
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
2	Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S43-S54.	2.8	1,919
3	Inhaled Iloprost for Severe Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 322-329.	27.0	1,626
4	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	27.0	1,168
5	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.	1.6	860
6	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801915.	6.7	607
7	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 702-710.	0.8	605
8	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1496-1502.	2.8	584
9	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134.	2.8	506
10	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2016, 133, 859-871.	1.6	506
11	Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D92-D99.	2.8	503
12	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740.	6.7	489
13	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	1.7	357
14	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. <i>European Respiratory Journal</i> , 2017, 49, 1601792.	6.7	339
15	Anticoagulation and Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 57-65.	1.6	317
16	Tracheotomy: clinical review and guidelines. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 412-421.	1.4	292
17	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	6.7	287
18	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 874-880.	6.7	267

#	ARTICLE	IF	CITATIONS
19	C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1211-1218.	2.8	220
20	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S97-S107.	2.8	209
21	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	10.7	201
22	Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S56-S61.	2.8	184
23	Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>European Respiratory Journal</i> , 2018, 51, 1701886.	6.7	139
24	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. <i>European Respiratory Review</i> , 2015, 24, 621-629.	7.1	128
25	Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 431-443.	6.7	127
26	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	6.7	124
27	Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 532-543.	5.3	120
28	Regional Right Ventricular Dysfunction in Chronic Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 1172-1180.	2.8	117
29	Diagnosis of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160108.	7.1	114
30	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1800332.	6.7	110
31	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.6	104
32	Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. <i>Annals of the American Thoracic Society</i> , 2016, 13, S201-S206.	3.2	101
33	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 224-232.	6.7	100
34	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2013, 110, 83-91.	3.4	96
35	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. <i>Nature Genetics</i> , 2013, 45, 518-521.	21.4	93
36	Pulmonary Vascular and Right Ventricular Reserve in Patients With Normalized Resting Hemodynamics After Pulmonary Endarterectomy. <i>Journal of the American Heart Association</i> , 2015, 4, e001602.	3.7	87

#	ARTICLE	IF	CITATIONS
37	Congenital veno-venous malformations of the liver: Widely variable clinical presentations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e390-4.	2.8	84
38	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	2.2	83
39	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	2.8	82
40	European Respiratory Society statement on long COVID follow-up. <i>European Respiratory Journal</i> , 2022, 60, 2102174.	6.7	81
41	Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 48, 470-483.	6.7	79
42	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	6.7	78
43	Iron deficiency is associated with adverse outcome in Eisenmenger patients. <i>European Heart Journal</i> , 2011, 32, 2790-2799.	2.2	76
44	Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2012, 40, 886-894.	6.7	74
45	CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 54, 1802308.	6.7	73
46	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155.	2.2	65
47	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. <i>ERJ Open Research</i> , 2021, 7, 00850-2020.	2.6	65
48	CCR5 as a Treatment Target in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 130, 880-891.	1.6	64
49	Interaction between respiration and right versus left ventricular volumes at rest and during exercise: a real-time cardiac magnetic resonance study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H816-H824.	3.2	64
50	TGF β 2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. <i>Drug Discovery Today</i> , 2019, 24, 703-716.	6.4	64
51	A different view on predictors of pulmonary hypertension in secundum atrial septal defect. <i>International Journal of Cardiology</i> , 2014, 176, 833-840.	1.7	63
52	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2018, 52, 1800248.	6.7	61
53	Optimising the management of pulmonary arterial hypertension patients: emergency treatments. <i>European Respiratory Review</i> , 2010, 19, 204-211.	7.1	60
54	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , 2014, 167, 210-217.	2.7	59

#	ARTICLE	IF	CITATIONS
55	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	6.7	57
56	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	10.7	57
57	Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1444-1456.	5.3	56
58	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>European Respiratory Journal</i> , 2020, 55, 2000189.	6.7	55
59	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.8	55
60	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	4.1	51
61	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 2284-2295.	2.2	51
62	Time course of reversed cardiac remodeling after pulmonary endarterectomy in patients with chronic pulmonary thromboembolism. <i>European Radiology</i> , 2008, 18, 792-799.	4.5	50
63	Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1879-1890.	2.4	46
64	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118.	0.8	46
65	Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. <i>European Heart Journal</i> , 2006, 27, 1472-1477.	2.2	44
66	Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 800-808.	0.6	43
67	The Evaluation of Pulmonary Hypertension Using Right Ventricular Myocardial Isovolumic Relaxation Time. <i>Journal of the American Society of Echocardiography</i> , 2005, 18, 1113-1120.	2.8	42
68	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	3.8	42
69	Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients. <i>Respiratory Research</i> , 2012, 13, 27.	3.6	41
70	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	5.6	41
71	The Belgian Eisenmenger syndrome registry: Implications for treatment strategies?. <i>Acta Cardiologica</i> , 2009, 64, 447-453.	0.9	41
72	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. <i>ERJ Open Research</i> , 2020, 6, 00520-2020.	2.6	40

#	ARTICLE	IF	CITATIONS
73	COMBINED LIVER AND (HEART-)LUNG TRANSPLANTATION IN LIVER TRANSPLANT CANDIDATES WITH REFRACTORY PORTOPULMONARY HYPERTENSION. <i>Transplantation</i> , 2002, 73, 140-156.	1.0	40
74	Regional right ventricular deformation in patients with open and closed atrial septal defect. <i>European Journal of Echocardiography</i> , 2011, 12, 206-213.	2.3	39
75	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	6.7	39
76	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. <i>European Respiratory Review</i> , 2019, 28, 190050.	7.1	39
77	Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. <i>Heart</i> , 2015, 101, 637-644.	2.9	38
78	Pulmonary Vascular Resistance as Assessed by Bicycle Stress Echocardiography in Patients With Atrial Septal Defect Type Secundum. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 237-245.	2.6	37
79	COVID-19 in lung transplant patients: A case series. <i>American Journal of Transplantation</i> , 2020, 20, 3234-3238.	4.7	37
80	Amorphous Silica Nanoparticles Promote Monocyte Adhesion to Human Endothelial Cells: Size-Dependent Effect. <i>Small</i> , 2013, 9, 430-438.	10.0	36
81	NF- κ B pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2013, 305, L934-L942.	2.9	36
82	Role for Telomerase in Pulmonary Hypertension. <i>Circulation</i> , 2015, 131, 742-755.	1.6	36
83	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.6	36
84	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	2.5	33
85	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801805.	6.7	31
86	Differential changes in regional right ventricular function before and after a bilateral lung transplantation: an ultrasonic strain and strain rate study. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 432-436.	2.8	30
87	The use of ECG and respiratory triggering to improve the sensitivity of oxygen-enhanced proton MRI of lung ventilation. <i>European Radiology</i> , 2003, 13, 1260-1265.	4.5	29
88	A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 173-179.	1.7	29
89	Double-lung versus heart-lung transplantation for precapillary pulmonary arterial hypertension: a 24-year single-center retrospective study. <i>Transplant International</i> , 2019, 32, 717-729.	1.6	29
90	Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study. <i>Echocardiography</i> , 2016, 33, 546-554.	0.9	28

#	ARTICLE	IF	CITATIONS
91	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.6	28
92	The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. <i>International Journal of Cardiology</i> , 2011, 152, 192-195.	1.7	27
93	Right Ventricular Function in Patients With Eisenmenger Syndrome. <i>American Journal of Cardiology</i> , 2012, 109, 1206-1211.	1.6	27
94	Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 1386-1392.	1.7	27
95	Balloon Pulmonary Angioplasty for the Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension: Single-Center Experience with Low Initial Complication Rate. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1265-1272.	0.5	27
96	Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1411-1419.	1.2	25
97	Atrial volume and function during exercise in health and disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 104.	3.3	25
98	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	2.9	23
99	Predictive model for late atrial arrhythmia after closure of an atrial septal defect. <i>International Journal of Cardiology</i> , 2013, 164, 318-322.	1.7	22
100	Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 337-351.	2.9	21
101	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	2.4	21
102	Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. <i>Perfusion (United Kingdom)</i> , 2005, 20, 101-108.	1.0	20
103	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. <i>Pflugers Archiv European Journal of Physiology</i> , 2016, 468, 1969-1983.	2.8	20
104	Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy. <i>Oncology Research and Treatment</i> , 2017, 40, 353-359.	1.2	19
105	Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2021, 143, 2061-2073.	1.6	19
106	Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. <i>European Respiratory Review</i> , 2009, 18, 253-259.	7.1	18
107	Cardiopulmonary Exercise Testing and SF-36 in Patients With Atrial Septal Defect Type Secundum. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011, 31, 308-315.	2.1	18
108	Apical traction: a novel visual echocardiographic parameter to predict survival in patients with pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 177-183.	1.2	18

#	ARTICLE	IF	CITATIONS
109	Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism. <i>European Radiology</i> , 2022, 32, 2178-2187.	4.5	18
110	Right ventricular load and function during exercise in patients with open and closed atrial septal defect type secundum. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 597-604.	1.8	17
111	Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661882344.	2.6	17
112	Prediction of hemodynamic improvement after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension using non-invasive imaging. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 143-150.	1.5	16
113	Low-flow support of the chronic pressure-overloaded right ventricle induces reversed remodeling. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 151-160.	0.6	15
114	Chronic post-embolic pulmonary hypertension: a new target for medical therapies?. <i>European Respiratory Review</i> , 2013, 22, 258-264.	7.1	14
115	Mechanical support of the pressure overloaded right ventricle: an acute feasibility study comparing low and high flow support. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H615-H624.	3.2	14
116	Clinical significance of dynamic pulmonary vascular resistance in two populations at risk of pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 564-570.	1.2	14
117	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	2.6	14
118	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 177-198.	0.5	13
119	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	2.9	13
120	Geometry of the right heart and tricuspid regurgitation to exclude elevated pulmonary artery pressure: New insights. <i>International Journal of Cardiology</i> , 2013, 168, 3866-3871.	1.7	12
121	Cytokines trigger disruption of endothelium barrier function and p38 ^{MAP} kinase activation in <i>BMPR2</i> -silenced human lung microvascular endothelial cells. <i>Pulmonary Circulation</i> , 2019, 9, 1-13.	1.7	12
122	Is the time constant of the pulmonary circulation truly constant?. <i>European Respiratory Journal</i> , 2014, 43, 1541-1542.	6.7	11
123	Systolic and diastolic unloading by mechanical support of the acute vs the chronic pressure overloaded right ventricle. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 457-465.	0.6	11
124	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 196.	2.7	11
125	Prediction of outcome after PEA in chronic thromboembolic pulmonary hypertension using indexed pulmonary artery diameter. <i>European Respiratory Journal</i> , 2014, 43, 909-912.	6.7	9
126	Pulmonary endarterectomy in a 12-year-old boy with multiple comorbidities. <i>Pulmonary Circulation</i> , 2019, 9, 1-4.	1.7	9

#	ARTICLE	IF	CITATIONS
127	Chronic thromboembolic pulmonary hypertension: diagnosis, operability assessment and patient selection for pulmonary endarterectomy. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 82-97.	1.7	9
128	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.	0.6	9
129	Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 148-156.	0.6	8
130	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005095.	2.2	8
131	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	1.7	8
132	Anaesthesia management for pulmonary endarterectomy. <i>Current Opinion in Anaesthesiology</i> , 2005, 18, 63-76.	2.0	7
133	The outcome of Eisenmenger patients with trisomy 21 does not differ from patients without trisomy 21. <i>Acta Cardiologica</i> , 2011, 66, 293-301.	0.9	7
134	Measurement of right ventricular pressure by telemetry in conscious moving rabbits. <i>Laboratory Animals</i> , 2013, 47, 184-193.	1.0	7
135	Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries. <i>Pflügers Archiv European Journal of Physiology</i> , 2006, 452, 213-221.	2.8	6
136	Bosentan for mild pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial. <i>International Journal of Cardiology</i> , 2013, 168, 5081-5082.	1.7	5
137	Abnormal Liver Uptake of ^{99m} Tc-Macroaggregated Albumin in a Patient with Superior Vena Cava Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1028-1028.	5.6	5
138	Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". <i>Circulation</i> , 2014, 130, e110-2.	1.6	5
139	Postoperative left ventricular function in different types of pulmonary hypertension: a comparative study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 813-819.	1.1	5
140	Magnetic resonance relaxometry of the liver - a new imaging biomarker to assess right heart failure in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 86-94.	0.6	5
141	Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?. <i>European Respiratory Journal</i> , 2014, 44, 842-845.	6.7	4
142	Letter by Belge et al Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models". <i>Circulation</i> , 2016, 133, e591.	1.6	4
143	Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, , .	3.1	4
144	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. <i>Chest</i> , 2013, 144, 876A.	0.8	3

#	ARTICLE	IF	CITATIONS
145	MELODY-1: A PILOT STUDY OF MACITENTAN IN PULMONARY HYPERTENSION DUE TO LEFT VENTRICULAR DYSFUNCTION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1880.	2.8	3
146	Serial pulmonary vascular resistance assessment in patients late after ventricular septal defect repair. <i>International Journal of Cardiology</i> , 2019, 282, 38-43.	1.7	3
147	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2020, 55, 2001047.	6.7	3
148	Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy. <i>European Respiratory Journal</i> , 2021, 57, 2002680.	6.7	3
149	Residual pulmonary hypertension after pulmonary thromboendarterectomy: incidence, pathogenesis and therapeutic options. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 163-165.	1.7	3
150	Impaired biventricular contractile reserve in patients with diastolic dysfunction: insights from exercise stress echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1042-1052.	1.2	3
151	Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol. <i>Respiration</i> , 2018, 95, 139-142.	2.6	2
152	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2020, 6, 00304-2020.	2.6	2
153	Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters. <i>Cells</i> , 2021, 10, 3229.	4.1	2
154	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2022, 8, 00665-2021.	2.6	2
155	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. <i>Advances in Therapy</i> , 2022, 39, 4374-4390.	2.9	2
156	Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. <i>Chest</i> , 2013, 144, 879A.	0.8	1
157	A Rare Central Thoracic Tumor. <i>Journal of Thoracic Oncology</i> , 2014, 9, 897-899.	1.1	1
158	Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress. <i>Journal of Thoracic Disease</i> , 2018, 10, S3029-S3033.	1.4	1
159	Assembly 13: placing the pulmonary circulation in the heart of ERS. <i>Breathe</i> , 2019, 15, 88-89.	1.3	1
160	Intravascular Leiomyomatosis as a Rare Cause of Nonthrombotic Pulmonary Embolism. <i>Case Reports in Vascular Medicine</i> , 2020, 2020, 1-4.	0.2	1
161	Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal malignancy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e22532-e22532.	1.6	1
162	Should We Focus on Hematocrit or Hemoglobin in Patients With Eisenmenger Syndrome?. <i>American Journal of Cardiology</i> , 2011, 108, 899-902.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. Chest, 2013, 144, 870B.	0.8	0
164	Highlights from the ERS International Congress 2018: Assembly 13 "Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.6	0
165	MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL. Chest, 2021, 160, A2284-A2286.	0.8	0
166	IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells. , 2016, , .		0
167	Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , .		0
168	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0
169	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
170	Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension. , 2017, , .		0
171	Administration of mitomycin results in pulmonary hypertension and vascular remodeling in rabbits. , 2017, , .		0
172	Survival in medically treated chronic thromboembolic pulmonary hypertension patients. , 2018, , .		0
173	Targeting CCR2 and CCR5 to inhibit macrophage/pulmonary artery smooth muscle cells cross-talk in pulmonary hypertension. , 2018, , .		0
174	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
175	Local inhibition of angiogenesis combined with repeated blood clot embolization induces chronic thromboembolic pulmonary hypertension in rabbits. , 2018, , .		0
176	Effect of BMPRII on endothelial function in human lung microvascular endothelial cells. , 2018, , .		0
177	Pulmonary arterial pressure predicts nocturnal hypoxemia in CTEPH patients.. , 2018, , .		0
178	Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension. , 2020, , .		0
179	Response by Howden et al to Letter Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension" Circulation, 2021, 144, e330-e331.	1.6	0
180	Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
181	Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension. , 2020, , .		0
182	ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52.	0.8	0
183	Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: A cohort study in Belgium. European Respiratory Journal, 0, , 2102335.	6.7	0